Thrombin generation in acute coronary syndrome and stable coronary artery disease: Dependence on plasma factor composition

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 104-110

  Brummel Ziedins, Kathleen ^a   Undas, A ^b   Orfeo, T ^a   Gissel, M ^a   Butenas, S ^a   Zmudka, K ^b   Mann, K G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Coagulation; Coronary disease; Thrombin; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA FACTOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIMULATION; STABLE ANGINA PECTORIS; THROMBIN TIME;

ACUTE CORONARY SYNDROME; ANTITHROMBIN III; BLOOD COAGULATION FACTORS; CORONARY ARTERY DISEASE; DIAGNOSIS, DIFFERENTIAL; FACTOR VIII; HUMANS; MODELS, STATISTICAL; PROTHROMBIN; THROMBIN;

EID: 37549018513     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02799.x     Document Type: Article

References (55)

1. Lee RT, Kamm RD. Vascular mechanics for the cardiologist. J Am Coll Cardiol 1994; 23: 1289-95.
2. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993; 22: 1228-41.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
4. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-14.
5. Hoffmeister HM, Ehlers R, Buttcher E, Steinmetz A, Kazmaier S, Helber U, Szabo S, Beyer ME, Seipel L. Relationship between minor myocardial damage and inflammatory acute-phase reaction in acute coronary syndromes. J Thromb Thrombolysis 2003; 15: 33-9.
6. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
7. Li YH, Teng JK, Tsai WC, Tsai LM, Lin LJ, Guo HR, Chen JH. Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-8.
8. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH. Antithrombotic therapy for coronary artery disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S-48S.
9. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
10. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
11. Butenas S, van't Veer C, Mann KG. 'Normal'thrombin generation. Blood 1999; 94: 2169-78.
12. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
13. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104: 2311-7.
14. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: Phenotypic quantitation. J Thromb Haemost 2004; 2: 281-8.
15. Brummel-Ziedins K, Whelihan MF, Ziedins EG, Mann KG. The resuscitative fluid you choose may potentiate bleeding. J Trauma 2006; 61: 1350-8.
16. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-33.
17. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 3: 2497-505.
18. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: Thrombin generation in healthy individuals. J Thromb Haemost 2005; 3: 1472-81.
19. Carr ME Jr, Martin EJ, Carr SL. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagul Fibrinolysis 2002; 13: 193-7.
20. Hartert HS. The phsical and biological constants of thrombelastography. Biorheology 1962; 1: 31-9.
21. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
22. Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2489-93.
23. Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992; 93: 651-7.
24. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42: 49-55.
25. Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412.
26. van 't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin- III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367-77.
27. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci USA 1981; 78: 162-6.
28. Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-25.
29. Cawthern KM, van 't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
30. Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-8.
31. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-13.
32. Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 23367-73 [published erratum appears in J Biol Chem 1995 Apr 14;270(15):9026].
33. Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG. The significance of circulating factor IXa in blood. J Biol Chem 2004; 279: 22875-82.
34. Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG. Blood coagulation and fibrinolysis. In: Lee GR, Forester J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's Clinical Hematology, 11th edn. Philadelphia: Lippincott Williams & Wilkins, 2003: 677-774.
35. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-66.
36. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
37. Nicolaes GA, Dahlback B. Activated protein C resistance (FV(Leiden)) and thrombosis: Factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003; 17: 37-61, vi.
38. Lu D, Bovill EG, Long GL. Molecular mechanism for familial protein C deficiency and thrombosis in protein C Vermont (Glu20->Ala and Val34->Met). J Biol Chem 1994; 269: 29032-8.
39. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
40. Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90: 835-8.
41. Bhattacharyya M, Kannan M, Chaudhry VP, Saxena R. Venous thrombosis: prevalence of prothrombotic defects in north Indian population. Indian J Pathol Microbiol 2003; 46: 621-4.
42. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997; 34: 188-204.
43. Harper PL, Luddington RJ, Daly M, Bruce D, Williamson D, Edgar PF, Perry DJ, Carrell RW. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991; 77: 360-4.
44. Vossen CY, Rosendaal FR. Risk of arterial thrombosis in carriers of familial thrombophilia. J Thromb Haemost 2006; 4: 916-8.
45. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-8.
46. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, Prins MH, van der MJ, Buller HR. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
47. Malecki R, Adamiec R. Factor VIII and the risk of arterial thrombosis. Postepy Hig Med Dosw (Online) 2006; 60: 602-8.
48. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L. The PLAT Study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb 1992; 12: 1063-70.
49. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
50. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1995; 15: 1269-79.
51. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: The AtheroGene study. Arterioscler Thromb Vasc Biol 2006; 26: 2793-9.
52. Derhaschnig U, Laggner AN, Roggla M, Hirschl MM, Kapiotis S, Marsik C, Jilma B. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 2002; 48: 1924-30.
53. Carville DG, Dimitrijevic N, Walsh M, Digirolamo T, Brill EM, Drew N, Gargan PE. Thrombus precursor protein (TpP): Marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996; 42: 1537-41.
54. Laurino JP, Pelletier TE, Eadry R, Kounavis A. Thrombus precursor protein and the measurement of thrombosis in patients with acute chest pain syndrome. Ann Clin Lab Sci 1997; 27: 338-45.
55. Linden MD, Furman MI, Frelinger AL III, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007; 5: 761-5.